Lamivudine for chronic hepatitis B

References

• Lai CL, Chien RN, Leung NWY, et al A 1 year trial of lamivudine for chronic hepatitis Br N Engl j Meal 339,61–68 (1998).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL, et al Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J. Med 341(17), 1256–1263 (1999).
   PubMed Web of Science ®Google Scholar
• Tassopoulos NC, Volepes R, Pastores G, et al Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Mutant Study Group. Hepatology 29(3), 889–896 (1999).
   PubMed Web of Science ®Google Scholar
• Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and interferon-a combination treatment of patients with chronic hepatitis B infection, a randomized trial. Gut 46,562–568 (2000).
   PubMed Web of Science ®Google Scholar
• Jarvis B, Faulds D. Lamivudine — a review of its therapeutic potential in chronic hepatitis B. Drugs 58(1), 101–104 (1999).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.Gastroenterology 119, 172–180 (2000).
   Google Scholar
• Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 51(4), 597–599 (2002).
   Google Scholar
• Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 30(3), 770–774 (1999).
   PubMed Web of Science ®Google Scholar
• Perillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36(10), 186–194 (2002).
   PubMedGoogle Scholar
• Guan R, Lai CL, Liaw YF, et al Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis. Gastroenterol Hepatol 16(Suppl.) 187(2001)
   Google Scholar
• Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B, 2000— summary of a workshop. Gastroenterology 120, 1828–1853 (2001).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Guan R, Lau GKK, Merican I. Asia—Pacific consensus statement on the management of chronic hepatitis B, an update. J. Gastroenterol Hepatol 18(3), 239–245 (2003).
   PubMedGoogle Scholar
• Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. Geneva, Switzerland, 14–16 September 2002.j Heptol 39\(Suppl. 1) S1—S235 (2003).
   Google Scholar
• Allen MI, Gauthier J, Des Lauriers M, et al. Two sensitive PCR-based methods for the detection of virus variants associated with reduced susceptibility to lamivudine. J. Clin. Microbial 37,3338–3347 (1999).
   PubMedGoogle Scholar
• Stuyver LJ, Lorcarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33(3), 751–757 (2001).
   PubMedGoogle Scholar
• Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30(2), 567–572 (1999).
   PubMed Web of Science ®Google Scholar
• ••Clinical course of patients with lamivudineresistant mutants.
   Google Scholar
• Lok A, Lai CL, Leung N, et al. Long term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125(6), 1417–1422 (2003).
   Google Scholar
• Lai CL, Dienstag J, Schiff E, et al Prevalence and clinical corelates of YMDD variants during lamivudine therapy for patients with chronic hepatitis. Br. Clin. Infect. Dis. 36(6), 687–689 (2003).
   PubMed Web of Science ®Google Scholar
• Wong VW, Chan HLY, Leung NW Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutant. Aliment. Pharmacol Ther. 19(3), 323–329 (2004).
   PubMedGoogle Scholar
• Perrillo R, Hann HWL, Mutimer D, et al Adefovir dipivoxil added to maintenance lamivudine in chronic hepatitis B with YMDD mutants HBV and a reduced response to lamivudine. Gastroenterology 126(1), 81-90(2004)
   PubMedGoogle Scholar
• Leung NWY, Lai CL, Chang TT, et al. and the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances heaptitis e antigen seroconversion rates, results after 3 years of therapy. Hepatology 33(6), 1527–1532 (2001).
   PubMed Web of Science ®Google Scholar
• ••Results from 3 years of lamivudine therapy among Asian patients, demonstrating histologic deterioration among patients with lamivudine resistant mutants.
   Google Scholar
• Dienstag JL, Goldin RD, Heathecoate EJ, et al. Histological outcome during long term lamividine therapy. Gastroenterology 124(1), 105–117 (2003).
   PubMed Web of Science ®Google Scholar
• Histologic outcome among patients from international trials showed improvement among patients with maintained virologic response but deterioration when viral breakthrough occurs.
   Google Scholar
• ••23Leung NWY, Lai CL, Guan R, Liaw Y-F. The effect of longer duration of harbouring lamivudine-resistant hepatitis B virus (YMDD mutants) on liver histology during 3 years lamivudine therapy in Chinese patients. Hepatology 34(4), 348A (2001) (Abstract 706).
   Google Scholar
• Leung NW, Liaw Y-F, Chang T-T, et al. Durable HBeAg response in Chinese patients treated with lamivudine. Hepatology 34(4), 348A (2001) (Abstract 705).
   Google Scholar
• Dienstag JL, Cianciara J, Karayalcin S, et al. Durabililty of serology after lamivudine treatment of chronic hepatitis B. Hepatology 37(4), 748–755 (2003).
   PubMed Web of Science ®Google Scholar
• Song B-C, Suh DJ, Lee HC, Chung Y-H, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32, 803–806 (2000).
   PubMed Web of Science ®Google Scholar
• Ryu SH, Chung YH, Choi MH, et al. Long term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss, a prospective study. J. Hepatol. 39(4), 614–619 (2003).
   PubMed Web of Science ®Google Scholar
• Van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B, relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52(3), 420–424 (2003).
   Google Scholar
• Chien R-N, Yeh C-T, Tsai S-L, Chu C-M, Liaw Y-F. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38,1267–1273 (2003).
   PubMed Web of Science ®Google Scholar
• Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. Hepatology 38(3), 322–327 (2003).
   Google Scholar
• •Role of lamivudine therapy in hepatic decompensation during acute exacerbation, the importance of early therapy.
   Google Scholar
• Chan HL, Tsang SW, Hui Y, Leung NW, Chan FK, Sung JJ. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J. Viral. Hepat. 9(6), 424–428 (2002).
   PubMedGoogle Scholar
• Villeneuve J-P, Condreay LD, Willems B, et al Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31, 207-210(2000).
   Google Scholar
• Liaw YF, Sung JY, Chow WC, Shue K, Keene O, Farrell G. Effect of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B. A prospective double-blind placebo-controlled clinical trial. Hepatology 38(4) (Suppl. 1), 262A (2003).
   Google Scholar
• •Benefit of long term lamivudine therapy among viremic patients with cirrhosis.
   Google Scholar
• Perillo RP, Wright T, Rakela J, et al. and the Lamivudine North American Transplant Group. A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33,424–432 (2001).
   PubMed Web of Science ®Google Scholar
• Nery JR, Nery-Avila C, Reddy KR, et al. Use of grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis IgG immunoglobulin and lamivudine. Transplantation 75(8), 1179–1186 (2003).
   PubMedGoogle Scholar
• Fabrega E, Garcia-Suarez C, Guerra A, et al Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 9(9), 916–920 (2003).
   PubMedGoogle Scholar
• Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J. Haematol 116(1), 166–169 (2002).
   PubMed Web of Science ®Google Scholar
• Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J. Haematol 115(1), 58–62 (2001).
   PubMedGoogle Scholar
• Jonas MM, Kelly DA, Mizerski J, et al. and the International Paediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J. Med. 346(22), 1706–1713. (Zucker SD. Commentary. All kidding aside with the use of lamivudine in children with chronic hepatitis B. Gastroenterology 123[5], 1741–1743) (2002).
   Google Scholar
• Jonas MM, Kelly DA, Mizerski J, et al. and the International Paediatric Lamivudine Investigator Group. Extended lamivudine therapy in children with chronic hepatitis B. Hepatology 38(4) (Suppl. 1), 710A (2002).
   Google Scholar
• Hartman C, Berkowitz D, Shouval DS, et al. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediat. Infect. Dis. J. 22(3), 224–229 (2003).
   PubMedGoogle Scholar
• Leung NWY. Lamivudine therapy for children with chronic hepatitis B. J. Hepatol. 38, 698–701 (2003).
   Google Scholar
• van Nunen AB, de Man R, Heijtink RA, Niesters HGM, Schalm SW. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B virus patients. J. Hepatol. 32(6), 1040–1041 (2000) (Letter).
   PubMed Web of Science ®Google Scholar
• Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudien therapy. Lancet 359, 1488–1489 (2002).
   PubMed Web of Science ®Google Scholar
• van Zonneveld M, van Nunen AB, Niesters HGM, de Man R, Schalm SW Janssen HLA. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J. Viral. Hepatol. 10,294–297 (2003).
   PubMed Web of Science ®Google Scholar
• Li XIV', Yang YB, Hou HY, et al. Interruption of HBV intrauterine transmission, a clinical study. World J. Gastroenterol. 9(7), 1501–1503 (2003).
   PubMed Web of Science ®Google Scholar
• Lai CL, Leung NWY, Teo EK, et al. Results of a 1-year international Phase JIB comparative trial of telbivudine, lamivudine and the combination, in patients with chronic hepatitis B. Hepatology 38(4) (Suppl. 1), 262A (2003).
   Google Scholar
• Schiff ER, DienstagJL, Karayalcin S, et al and the International Lamivudine Investigator Group. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. HepatoL 38(6), 818–826 (2003).
   Google Scholar
• Sung JJY, Chan HLY, Hui AY, et al. Combination of pegylated interferon and lamivudine is superior to lamivudine monotherapy in the treatment of chronic hepatitis B — a randomized trial. J. Hepatol. 38\(Suppl. 2), 33 (2003).
   Google Scholar
• Marcellin P, Lau GKK, Bonino F, et al. A, Phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon-ct, (40 KD) (Pegasis®) alone or in combination with lamivudine vs. lamivudine in 546 patients with HBeAg-negative/anti-HBe positive chronic hepatitis B. Hepatology 38(4) (Suppl. 1), 724A (2003).
   Google Scholar